• Skip to primary navigation
  • Skip to main content

PEPTIDES - LATEST HOT 🔥 INFO

Peptide News and Research

  • Home
  • Podcast
  • Hot 🔥 Articles
  • About Us
    • Who We Are
    • Privacy Policy
  • Partners

Dr. Nikki

SS-31

September 18, 2024 Dr. Nikki 2 Comments

What is SS-31? Ela-mep-ra-tide SS-31, also known as Elamipretide, is a synthetic peptide that has gained attention in the scientific and medical communities for its potential role in treating various age-related and degenerative diseases. It is a small, mitochondria-targeting peptide specifically designed to protect and improve the function of mitochondria, the energy-producing “powerhouses” of our […]

Filed Under: Podcast Tagged With: peptides, ss31

Differences Between Semaglutide and Tirzepatide

September 11, 2024 Dr. Nikki Leave a Comment

Two of the most promising treatments for obesity in recent years are semaglutide, a GLP-1 agonist, and tirzepatide, a dual GLP-1/GIP agonist. These peptides have garnered attention for their impressive efficacy in weight loss and metabolic improvement, but they differ in their mechanisms, dosing, side effects, and outcomes. In this podcast, we’ll explore how these […]

Filed Under: Podcast Tagged With: glp1, peptides, semaglutide, tirzepatide, weightloss

Potential of GLP-1 Agonists in Alzheimer’s Disease

August 15, 2024 Dr. Nikki Leave a Comment

Alzheimer’s disease is a type of dementia characterized by memory loss, cognitive decline, and a decline in the ability to perform daily tasks (e.g., planning and organizing). It can also affect mood and personality and impair judgment and language. Research has shown that Alzheimer’s results from amyloid plaques and neurofibrillary tangles in brain tissue, which […]

Filed Under: Podcast Tagged With: peptides, semaglutide

Weight Loss Plateau with GLP-1 Agonists

August 8, 2024 Dr. Nikki Leave a Comment

In the journey of weight loss, everyone eventually reaches a plateau, even when using newer GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound). This phase is where the body finds a new set point and weight. During this plateau, some individuals may experience a gradual increase in appetite or “food noise”, while others can […]

Filed Under: Podcast Tagged With: glp1, semaglutide

Debunking the Myth: “You Can’t Stop Taking GLP-1 Agonists”

July 31, 2024 Dr. Nikki Leave a Comment

One common misconception about GLP-1 agonists, such as semaglutide (Wegovy) and tirzepatide (Zepbound), is that once you start taking them, you can never stop. This myth can deter individuals from considering these highly effective medications for weight loss.  In this podcast, we’ll debunk this myth and provide a clearer understanding of how GLP-1 agonists can […]

Filed Under: Podcast Tagged With: peptides, semaglutide, weightloss

Appetite Changes on GLP-1 Agonists

July 23, 2024 Dr. Nikki Leave a Comment

GLP-1 agonists, such as semaglutide (Wegovy), are popular medications for weight loss that work by mimicking the action of the GLP-1 hormone, which helps regulate appetite and blood sugar levels. While these medications can be very effective, some individuals might experience fluctuations in their appetite over time. If you’ve noticed that your appetite seems to […]

Filed Under: Podcast Tagged With: peptides, semaglutide

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Interim pages omitted …
  • Page 25
  • Go to Next Page »

Copyright © 2025

PEPTIDES

The contents of this website, such as text, graphics, images, and other material contained on the website (“Content”) are for informational purposes. Our site is not intended to be a substitute for professional medical advice, diagnosis, or treatment from a licensed healthcare professional. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

Never disregard professional medical advice or delay in seeking it because of something you have read on this website.